Difference between revisions of "Part:BBa K3924027"
Yiyuan-h19 (Talk | contribs) |
Leslie Young (Talk | contribs) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
<partinfo>BBa_K3924027 short</partinfo> | <partinfo>BBa_K3924027 short</partinfo> | ||
| − | + | This device consists of csgA as secretion peptide, Gly/Ser linker to ensure that the function of secretion peptide and therapeutic protein do not affect each other and TFF1 as therapeutic protein. | |
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
| Line 12: | Line 12: | ||
<partinfo>BBa_K3924027 SequenceAndFeatures</partinfo> | <partinfo>BBa_K3924027 SequenceAndFeatures</partinfo> | ||
| + | ==Usage and Biology== | ||
| + | In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by<i> E.coli Nissle 1917</i> (EcN) <i>in situ</i>. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins. | ||
| + | [[Image: T--Tsinghua--General design of the treatment ternary system.png|center|600px|thumb|'''Fig.1 General design of the treatment ternary system''']] | ||
| + | TFF1 is one of the candidate therapeutic proteins we screened out to treat IBD, which is the effector element in the ternary system. TFFs facilitate a significant role not only in mucosal repair but also in protecting mucous epithelia from a variety of insults in the gastrointestinal tract. The potential mechanisms to treat IBD involves anti-apoptotic properties, migration and invasion, angiogenesis, and interaction with mucins<sup>[1]</sup>. | ||
| + | ==Functional Verification== | ||
| + | [[Image: T--Tsinghua--The scheme of the proof-of-concept for therapeutic proteins.png|center|600px|thumb|'''Fig 2. The scheme of the proof-of-concept for therapeutic proteins.''']] | ||
| + | All of these proteins are worth studying, but we only chose a few proteins as a proof of concept in our actual wet lab experiments because of the time limit and the high expense of gene synthesis. <br/> | ||
| + | For all candidate therapeutic proteins we did codon analysis with our own software tool.(Fig 3) | ||
| + | [[Image: T--Tsinghua--Codon preference confident analysis.png|center|600px|thumb|'''Fig 3. Codon preference confident analysis of all candidate therapeutic proteins(Compared with GenSmart).''']] | ||
| + | As for TFF1, the result of codon preference is shown in Fig 4. | ||
| + | [[Image: T--Tsinghua--Codon preference confident analysis of TFF1.png|center|600px|thumb|'''Fig 4. Codon preference confident analysis of TFF1.''']] | ||
| + | ==Reference== | ||
| + | [1] Aamann, L., Vestergaard, E. M., & Grønbæk, H. (2014). Trefoil factors in inflammatory bowel disease. World journal of gastroenterology, 20(12), 3223–3230. <br/> | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
Latest revision as of 20:33, 21 October 2021
csgA-6xHis-TFF1
This device consists of csgA as secretion peptide, Gly/Ser linker to ensure that the function of secretion peptide and therapeutic protein do not affect each other and TFF1 as therapeutic protein.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 371
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 371
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 371
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 371
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI.rc site found at 664
Usage and Biology
In order to heal the intestinal tract damage, one of notable symptoms of IBD, we adopted a special therapy expressing the therapeutic proteins controllably by E.coli Nissle 1917 (EcN) in situ. The design is based on a ternary system: sensor - secretion peptide - therapeutic proteins.
TFF1 is one of the candidate therapeutic proteins we screened out to treat IBD, which is the effector element in the ternary system. TFFs facilitate a significant role not only in mucosal repair but also in protecting mucous epithelia from a variety of insults in the gastrointestinal tract. The potential mechanisms to treat IBD involves anti-apoptotic properties, migration and invasion, angiogenesis, and interaction with mucins[1].
Functional Verification
All of these proteins are worth studying, but we only chose a few proteins as a proof of concept in our actual wet lab experiments because of the time limit and the high expense of gene synthesis.
For all candidate therapeutic proteins we did codon analysis with our own software tool.(Fig 3)
As for TFF1, the result of codon preference is shown in Fig 4.
Reference
[1] Aamann, L., Vestergaard, E. M., & Grønbæk, H. (2014). Trefoil factors in inflammatory bowel disease. World journal of gastroenterology, 20(12), 3223–3230.